Aurinia Announces Positive CHMP Opinion for LUPKYNIS® for the Treatment of Adults with Active Lupus Nephritis in Europe Pharmaceutical Investing
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic Pharmaceutical Investing
Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry Pharmaceutical Investing
Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Ankylosing Spondylitis Pharmaceutical Investing
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity Pharmaceutical Investing
Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs Company News
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma Pharmaceutical Investing
Bristol Myers Squibb Launches Disability Diversity in Clinical Trials Initiative to Improve Healthcare Outcomes for People with Disabilities Pharmaceutical Investing
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022 Market News
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® Pharmaceutical Investing
Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS Life Science Investing
